An update on plexiform fibrohistiocytic tumor and addition of 66 new cases from the Armed Forces Institute of Pathology, in honor of Franz M. Enzinger, MD
Moosavi C., Jha P., Fanburg-Smith JC.
Prospective Study with a reported sample of 65 on Chronic Inflammation, published in Ann Diagn Pathol (2007) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Ann Diagn Pathol (2007)
- Reported sample size
- 65
- Source database
- Europe PMC
- PMID
- 17870015
- DOI
- 10.1016/j.anndiagpath.2007.01.003
- Citations
- 54
Abstract (original English)
The seminal article of Drs Franz Enzinger and Renyuan Zhang in 1988 defined plexiform fibrohistiocytic tumor (PFHT) as a distinctive entity. They described 65 cases (from 1965 to 1985) in children and young adults, with female and upper extremity predominance. These tumors were morphologically divided into 3 groups: fibroblastic, histiocytic (often with osteoclast-type giant cells), and mixed. Most tumors exhibited a plexiform and infiltrative arrangement of cells at the dermal/subcutaneous junction. Two fibroblastic PFHT had a metaplastic bone formation. Absence of cellular pleomorphism, low mitotic activity, dense hyalinization, hemorrhage, and chronic inflammation were observed. Vascular invasion was present in 1 recurrent, yet nonmetastatic, case. Tumors were negative for S100 protein, desmin, cytokeratin, factor VIIIrag, and lysozyme. Most patients were without disease up to 60 years after excision; 32 (37.5%) cases with follow-up recurred and 2 of those patients had regional lymph node metastasis at 9 and 36 months, respectively, yet there were no systemic metastases. In the interim, there have been additional studies on PFHT. We wanted to update the literature and add 66 new PFHT cases (1986-present) from the Armed Forces Institute of Pathology, since this seminal article, in honor of Dr Franz Enzinger. There were 37 men and 29 women; patient age ranged from 1 to 77 year
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Comparing Regenerative Biologics and Standard Pharmacotherapy for Chronic Rotator Cuff Tendinopathy: A Study of PRP, Cell-Based, and Peptide Interventions
Systematic Review on Tendon Injury, Rotator Cuff, Shoulder Pain, Chronic Inflammation, published in J Orthop Sports Med (2026) — summary generated from the PubMed abstract.
- 2026
J Orthop Sports Med - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol - Level AMeta-analysisPubMed
Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.
Meta-analysis with a reported sample of 602 on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, Immune Modulation, published in PeerJ (2026) — summary generated from the PubMed abstract.
- 2026
- n = 602
PeerJ - Level ASystematic ReviewEurope PMC
Exosomes as Cellular Communicators and Therapeutic Agents in Orthopedic Diseases: From Mechanisms to Intervention
Systematic Review on Osteoarthritis, Chronic Inflammation, published in Int J Nanomedicine (2026) — summary generated from the PubMed abstract.
- 2026
Int J Nanomedicine1 citations - Level ASystematic ReviewEurope PMC
Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review
Systematic Review on Chronic Inflammation, Immune Modulation, published in Front Oncol (2026) — summary generated from the PubMed abstract.
- 2026
Front Oncol - Level ASystematic ReviewEurope PMC
Trends in peripheral nerve injury research: a bibliometric analysis focused on molecular mechanisms
Systematic Review on Chronic Inflammation, published in Front Neurol (2026) — summary generated from the PubMed abstract.
- 2026
Front Neurol